Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Neoplasms 1Ovarian Neoplasms 1FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma 1Endometrial Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Cisplatin 32human papillomavirus vaccine, L1 type 16, 18 16Brachytherapy 15Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 12Paclitaxel 11Bevacizumab 11pembrolizumab 10Platinum 91,2-diaminocyclohexaneplatinum II citrate 9Topotecan 8Radiotherapy, Intensity-Modulated 8Radiation 8Papillomavirus Vaccines 8atezolizumab 6Gemcitabine 6Fluorodeoxyglucose F18 6Cyclophosphamide 6tisotumab vedotin 5fludarabine phosphate 5fludarabine 5aldesleukin 5Taxes 5Radiotherapy 5Magnetic Resonance Spectroscopy 5Carboplatin 5Vaccines, Synthetic 4Nivolumab 4Immunoglobulin G 4Disulfides 4Colposcopy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Uterine Cervical Neoplasms × Hysterectomy × Clear all
NCT00610740 2017-12-28

CerviPrep for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial, Cervical, or Ovarian Epithelial Cancer

Masonic Cancer Center, University of Minnesota

Phase 2 Completed
18 enrolled 8 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡